Sernova ranks among the 50 best performing companies on TSX Venture Exchange’s 2022 list


DGAP-News: Sernova Corp. / Keyword(s): Miscellaneous
24.02.2022 / 13:31
The issuer is solely responsible for the content of this announcement.

Sernova has been receiving Best Performer status for two years

LONDON, ONTARIO – February 24, 2022 – Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage cell therapy and regenerative medicine company focused on developing a potential cure for type 1 diabetes (T1D ) and other chronic illnesses, is pleased to announce that it has been named one of the TSX Venture Exchange’s Top 50 Performers.

The 2022 TSX Venture Exchange Top 50 is a ranking of the best performing companies on the TSX Venture Exchange over the past year based on three equally weighted criteria: share price appreciation, average volume of transactions and market capitalization growth.

“We are honored by the TSX Venture Exchange’s recognition of Sernova as one of the 2022 Top 50 Companies. shareholders as we continue to execute on our strategic plan to build a leadership position in the therapeutic area of ​​cell therapy in regenerative medicine. In 2022, we look forward to continuing our success by scaling our clinical programs, further developing our pharmaceutical partnerships and advancing our capital markets initiatives,” said Dr. Philip Toleikis, Chairman and CEO of Sernova.

As part of the award, the TSX Venture Exchange sponsored an interview with Dr. Toleikis. To view the video, please
and for the full list of 2022 TSX Venture 50 companies.


Sernova develops regenerative medicine therapeutic solutions using a medical device (Cell Pouch) and immunoprotected therapeutic cells/tissues (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve treatment and quality of life for people with metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated by cellular production of proteins or hormones that are lacking or in insufficient quantity in the body. For more information, please visit


The Cell Pouch, as part of the Cell Pouch System, is a novel, scalable, proprietary implantable macro-encapsulation device solution designed for the survival and long-term functioning of therapeutic cells. Upon implantation, the device is designed to embed itself into tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as needed to treat the disease.

The cell pocket, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and to provide a biologically compatible environment for cells that produce diabetes. insulin in humans in a Canadian first-in-man study. Sernova is currently conducting a phase I/II study at the University of Chicago. The first positive results were presented at several international scientific conferences.


Christopher Barnes
Vice President, Investor Relations
Sernova Corp.
[email protected]
Tel: 519-902-7923

Corey Davis, Ph.D.
LifeSci Advisors, LLC
[email protected]
Tel: 212-915-2577

This press release contains statements which, to the extent that they are not recitals of historical fact, may constitute “forward-looking statements” that involve various risks, uncertainties and assumptions, including, without limitation, statements regarding prospects, plans and objectives of the company. Whenever possible, but not always, words such as “anticipates”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “could”, “might” or “should” occur are used to identify forward-looking statements. These statements reflect management’s beliefs regarding future events and are based on information currently available to management as of the date such statements were made. Many factors could cause Sernova’s actual results, performance or achievements not to be those anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this press release. These factors could include, but are not limited to, the Company’s ability to obtain additional financing and license agreements on reasonable terms, if at all; ability to conduct all preclinical and clinical studies required for the Company’s Cell Pouch System and/or related technologies, including the timing and results of such trials; ability to obtain all necessary or timely regulatory approvals; the ability to license additional complementary technologies; its ability to implement its business strategy and compete successfully in the marketplace; and the inherent risks associated with the development of combination biotechnology products generally. Many factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors are encouraged to consult the Company’s quarterly and annual filings available at for additional information on the risks and uncertainties associated with forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

24.02.2022 Broadcast of a Corporate News, transmitted by the DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at


About Author

Comments are closed.